Breaking News: Gilead’s patent application for Sofosbuvir rejected in India

Gilead’s patent application for base compound of Sofosbuvir pending in Delhi Patent Office was rejected by Patent Controller General of India. See the decision here.

This decision will pave the way for a healthy generic competition in India as companies who have not sign Gilead’s Voluntary License can enter the market and ensure access to even those countries which have been left out in the license.

This entry was posted in Hepatitis C, Patents and tagged , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s